118 related articles for article (PubMed ID: 2879412)
21. The effects of SCH 23390, YM 09151-2, (+)- and (-)-3-PPP and some classical neuroleptics on D-1 and D-2 receptors in rat neostriatum in vitro.
Plantjé JF; Hansen HA; Daus FJ; Stoof JC
Eur J Pharmacol; 1984 Oct; 105(1-2):73-83. PubMed ID: 6208045
[TBL] [Abstract][Full Text] [Related]
22. Synergy between a selective D1 antagonist and a selective D2 antagonist in the induction of catalepsy.
Parashos SA; Marin C; Chase TN
Neurosci Lett; 1989 Oct; 105(1-2):169-73. PubMed ID: 2485878
[TBL] [Abstract][Full Text] [Related]
23. Dopamine receptor agonistic and antagonistic effects of 3-PPP enantiomers.
Arnt J; Bøgesø KP; Christensen AV; Hyttel J; Larsen JJ; Svendsen O
Psychopharmacology (Berl); 1983; 81(3):199-207. PubMed ID: 6139838
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
Chipkin RE; Iorio LC; Coffin VL; McQuade RD; Berger JG; Barnett A
J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002
[TBL] [Abstract][Full Text] [Related]
25. Dopamine D-1 receptor agonists combined with the selective D-2 agonist quinpirole facilitate the expression of oral stereotyped behaviour in rats.
Arnt J; Hyttel J; Perregaard J
Eur J Pharmacol; 1987 Jan; 133(2):137-45. PubMed ID: 2949991
[TBL] [Abstract][Full Text] [Related]
26. The cataleptogenic effects of the neuroleptic nemonapride are attenuated by its 5-HT1A receptor agonist properties.
Prinssen EP; Kleven MS; Koek W
Eur J Pharmacol; 1998 Sep; 356(2-3):189-92. PubMed ID: 9774248
[TBL] [Abstract][Full Text] [Related]
27. Chronic neuroleptic-induced mouth movements in the rat: suppression by CCK and selective dopamine D1 and D2 receptor antagonists.
Stoessl AJ; Dourish CT; Iversen SD
Psychopharmacology (Berl); 1989; 98(3):372-9. PubMed ID: 2568657
[TBL] [Abstract][Full Text] [Related]
28. Involvement of D1 dopamine receptors in the nicotine-induced neuro-endocrine effects and depletion of diencephalic catecholamine stores in the male rat.
Andersson K; Fuxe K; Eneroth P; Härfstrand A; Agnati LF
Neuroendocrinology; 1988 Aug; 48(2):188-200. PubMed ID: 2975769
[TBL] [Abstract][Full Text] [Related]
29. Haloperidol-induced catalepsy is absent in dopamine D(2), but maintained in dopamine D(3) receptor knock-out mice.
Boulay D; Depoortere R; Oblin A; Sanger DJ; Schoemaker H; Perrault G
Eur J Pharmacol; 2000 Mar; 391(1-2):63-73. PubMed ID: 10720636
[TBL] [Abstract][Full Text] [Related]
30. The electrically-stimulated spinal reflex in pithed rats: a possible test model for evaluating blockade of central dopamine D1 and D2 receptors.
Skarsfeldt T
Pharmacol Toxicol; 1989 Mar; 64(3):298-301. PubMed ID: 2566992
[TBL] [Abstract][Full Text] [Related]
31. Co-administration of either a selective D1 or D2 dopamine antagonist with methamphetamine prevents methamphetamine-induced behavioral sensitization and neurochemical change, studied by in vivo intracerebral dialysis.
Hamamura T; Akiyama K; Akimoto K; Kashihara K; Okumura K; Ujike H; Otsuki S
Brain Res; 1991 Apr; 546(1):40-6. PubMed ID: 1677305
[TBL] [Abstract][Full Text] [Related]
32. Synergistic blockade of some dopamine-mediated behaviours by (-)-sulpiride and SCH 23390 in the rat.
Dall'Olio R; Roncada P; Vaccheri A; Gandolfi O; Montanaro N
Psychopharmacology (Berl); 1989; 98(3):342-6. PubMed ID: 2568655
[TBL] [Abstract][Full Text] [Related]
33. D1/D2 dopamine and N-methyl-D-aspartate (NMDA) receptor participation in experimental catalepsy in rats.
Verma A; Kulkarni SK
Psychopharmacology (Berl); 1992; 109(4):477-83. PubMed ID: 1365866
[TBL] [Abstract][Full Text] [Related]
34. Differential involvement of dopamine D-1 and D-2 receptors in the circling behaviour induced by apomorphine, SK & F 38393, pergolide and LY 171555 in 6-hydroxydopamine-lesioned rats.
Arnt J; Hyttel J
Psychopharmacology (Berl); 1985; 85(3):346-52. PubMed ID: 2860689
[TBL] [Abstract][Full Text] [Related]
35. Pharmacology of JNJ-42314415, a centrally active phosphodiesterase 10A (PDE10A) inhibitor: a comparison of PDE10A inhibitors with D2 receptor blockers as potential antipsychotic drugs.
Megens AA; Hendrickx HM; Hens KA; Fonteyn I; Langlois X; Lenaerts I; Somers MV; de Boer P; Vanhoof G
J Pharmacol Exp Ther; 2014 Apr; 349(1):138-54. PubMed ID: 24421319
[TBL] [Abstract][Full Text] [Related]
36. Effects of S (+)-3-phenethyl-PP, a putative dopamine autoreceptors agonist with greater autoreceptor selectivity than 3-PPP enantiomers.
Arnt J; Bøgesø KP; Hyttel J; Larsen JJ; Svendsen O
Eur J Pharmacol; 1984 Jun; 102(1):91-9. PubMed ID: 6148247
[TBL] [Abstract][Full Text] [Related]
37. Similarity of clozapine and SCH 23390 in reserpinized rats suggests a common mechanism of action.
Chipkin RE; Latranyi MB
Eur J Pharmacol; 1987 Apr; 136(3):371-5. PubMed ID: 2886345
[TBL] [Abstract][Full Text] [Related]
38. Effects of dextromethorphan on dopamine dependent behaviours in rats.
Gaikwad RV; Gaonkar RK; Jadhav SA; Thorat VM; Jadhav JH; Balsara JJ
Indian J Exp Biol; 2007 Aug; 45(8):712-9. PubMed ID: 17877148
[TBL] [Abstract][Full Text] [Related]
39. The potential antipsychotic activity of the partial dopamine receptor agonist (+)N-0437.
Timmerman W; Tepper PG; Bohus BG; Horn AS
Eur J Pharmacol; 1990 Jun; 181(3):253-60. PubMed ID: 1974516
[TBL] [Abstract][Full Text] [Related]
40. Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats.
Kleven MS; Barret-Grévoz C; Bruins Slot L; Newman-Tancredi A
Neuropharmacology; 2005 Aug; 49(2):135-43. PubMed ID: 15996562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
